高剂量维生素D补充的安全性:一项随机对照试验的二次分析
结果显示三组血清钙、肌酐及24小时尿钙排泄无差异,但高钙尿症和高钙血症发生率随剂量增加而升高,高钙血症罕见且轻微一过性。
核心结论
- 高钙尿症常见且随剂量增加而更频繁。
- 高钙血症随剂量增加而更频繁,但罕见、轻微且一过性。
研究设计与样本
- Calgary维生素D研究为为期3年的双盲随机对照试验,单中心于加拿大卡尔加里大学进行。
- 若膳食钙摄入低于1200 mg/日则开始补钙。
主要发现
- 三组血清钙、肌酐及24小时尿钙排泄无差异。
- 临床不良事件发生于365名(97.9%)参与者,各组间均衡。
关键数值与推荐
- 轻度高钙血症定义为血清钙2.56-2.64 mmol/L。
局限性
- 本研究为二次分析,预设次要终点。
- 研究对象为55-70岁健康成人,血清25-羟基维生素D 30-125 nmol/L,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: More than 3% of adults report vitamin D intakes of 4000 IU/day or more, but the safety of this practice is unknown. OBJECTIVE: The objective of this work is to establish whether vitamin D doses up to 10 000 IU/day are safe and well tolerated. DESIGN: The Calgary Vitamin D Study was a 3-year, double-blind, randomized controlled trial. SETTING: A single-center study was conducted at the University of Calgary, Canada. PARTICIPANTS: Participants included healthy adults (n = 373) ages 55 to 70 years with serum 25-hydroxyvitamin D 30 to 125 nmol/L. INTERVENTIONS: Participants were randomly assigned 1:1:1 to vitamin D3 400, 4 000, or 10 000 IU/day. Calcium supplementation was initiated if dietary calcium intake was less than 1200 mg/day. MAIN OUTCOME MEASURES: In these prespecified secondary analyses, changes in serum 25-hydroxyvitamin D, calcium, creatinine, 24-hour urine calcium excretion, and incidence of adverse events were assessed. Between-group differences in adverse events were examined using incident rate differences and logistic regression. RESULTS: Of 373 participants (400: 124, 4000: 125, 10 000: 124), 49% were male, mean (SD) age was 64 (4) years, and 25-hydroxyvitamin D 78.0 (19.5) nmol/L. Serum calcium, creatinine, and 24-hour urine calcium excretion did not differ between treatments. Mild hypercalcemia (2.56-2.64 mmol/L) occurred in 15 (4%) participants (400: 0%, 4000: 3%, 10 000: 9%, P = .002); all cases resolved on repeat testing. Hypercalciuria occurred in 87 (23%) participants (400: 17%, 4000: 22%, 10 000: 31%, P = .01). Clinical adverse events were experienced by 365 (97.9%) participants and were balanced across treatment arms. CONCLUSIONS: The safety profile of vitamin D supplementation is similar for doses of 400, 4000, and 10 000 IU/day. Hypercalciuria was common and occurred more frequently with higher doses. Hypercalcemia occurred more frequently with higher doses but was rare, mild, and transient.
引用
- Billington EO, Burt LA, Rose MS, et al. Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial. J Clin Endocrinol Metab. 2020. PMID: 31746327. doi:10.1210/clinem/dgz212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。